Skip to main content
Premium Trial:

Request an Annual Quote

Sanger s Bradley a Royal Fellow; Affy EVP On Year-Long Leave; Macevicz Joins Aclara; and Others

NEW YORK, May 15 - Epoch Biosciences hired Cy Cabradilla as vice president of operations, the company said yesterday.

 

Cabradilla will manage the company's custom oligonucleotide manufacturing. His title is a newly created position.

 

He was previously vice president of genomics for BioSource International.

 

Epoch, based in Bothell, Wash., is a publicly held reagent and technology company.

 


 

Stephen Macevicz has joined Aclara Biosciences  as vice president of intellectual property, according to SEC filings.

 

Macevicz, 53, was previously vice president of intellectual property at GeneProt, which he joined last year. Prior to that, he was VP of IP for Lynx Therapeutics, and before that was senior patent attorney and chief patent counsel at Applied Biosystems.

 

He started at Aclara in March 2002.

 

GeneProt general counsel Marc Funk will continue to have oversight of legal affairs and IP, said a company representative.

 


 

Wellcome Trust Sanger Institute director Allan Bradley was elected to the Fellowship of the Royal Society, one of the most prestigious scientific commendations in the United Kingdom.

 

Bradley and 41 other scientists, engineers and technology experts were chosen for the honor this year, announced on May 13.

 

Bradley, 42, assumed the directorship of the institute in 2000. He is known for his work in developing a system for isolating, growing, and modifying embryonic stem cells to produce mutant mice.

 

He is also a founder of Lexicon Genetics.

 

Founded in 1660, the Royal Society is an independent academy that promotes and subsidizes scientific research.

 


 

Illumina said on May 10 that it had promoted John Stuelpnagel to senior vice president of operations. Stuelpnagel will oversee manufacturing, IP, scientific operations, engineering, R&D, and business development for the company.

 

Stuelpnagel, 44, is one of the company's founders and serves on Illumina's board. He was previously vice president of business development, served as acting president and chief executive officer from April 1998 through October 1999, and was acting chief financial officer through April 2000.

 


 

Bangalore bioinformatics company Strand Genomics said on May 7 that it had appointed Charles Cantor to its scientific advisory board.

 

Cantor, 59, is chief scientific officer at Sequenom. He previously directed the Center for Advanced Biotechnology at Boston University, and prior to that was director of the Human Genome Center at Lawrence Berkeley Laboratory.

 

Strand is a spin off of the Indian Institute of Science in Bangalore. The company is currently developing a suite of software products to improve drug discovery productivity.

 


 

Affymetrix executive vice president for global operations Ronald Verdoorn will be on personal leave through March 2003, according to the filings with the SEC. His leave began on April 1.

 

Verdoorn joined the company as executive vice president for global manufacturing in January 1999. He was responsible for developing and implementing manufacturing plans for the company's gene chips, and oversaw operations in the company's Sunnyvale and West Sacramento factories.

 

Verdoorn will "remain available to work on transition plans for manufacturing operations" under the new title of senior transition team member of global operations, pulling down a base salary of $1,000 a month in addition to a $2,500 fee for each day worked, company documents indicate.

 

Affymetrix did not respond to requests for further information regarding ongoing leadership of global operations and manufacturing.

 


 

Caliper Technologies has brought on new board member, Robert Bishop, an appointment overshadowed by executive personnel changes last week.

 

Bishop, 59, is board chair at AutoImmune, and was previously in senior management at Allergan, and eye- and skin-care product company. He is also a director for Millipore and for Quintiles Transnational.

 

In addition, the company has proposed to shareholders that former CEO Daniel Kisner become board chair, and that new CEO Michael Knapp and new president James Knighton be named to the board.

 


 

Incyte executive vice president for marketing and sales James Neals resigned from the firm in April, according to SEC filings.

 

Neal was hired to that position in July 1999, where he took charge of the company's worldwide marketing and sales efforts.

 

Before joining Incyte, he was general manager of the Monsanto division Solaris Group, and had been with Monsanto since 1982.

 

The company did not respond to requests for further information.

 



Promoted? Changing jobs? GenomeWeb wants to know. E-mail Kat McGowan at [email protected] to appear in PEOPLE, a roundup of personnel comings and goings in genomics that runs every Wednesday.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.